Study of Fat Malabsorption by Lipiblock Versus Xenical

• Status: Completed
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: Female

Summary

Obesity is a chronic condition with fat-rich diets playing a major role in its etiology. Pharmacological therapy has been proposed for weight loss and maintenance. This study aims to study the intestinal lipase blockade by partial inhibition of fat absorption after treatment with two commercials formulations of Orlistat.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Campinas, Brazil
• Collaborator: Germed Pharma
• Treatments: Orlistat

Criteria

Inclusion Criteria:

• Obesity

• BMC (Body Mass Index) between 30 to 40 kg/m2

• Women

• 18 to 45 years

• Premenopausal stage

Exclusion Criteria:

• Relevant diseases (diabetes, cardiovascular, gastrointestinal, renal and hepatic diseases, endocrine disorders, hemoglobinopatHy or neoplasm in the last three years)

• Chemical or natural laxatives

• Weight variation greater than 5% in the preceding 3 months

• Surgery for weight reduction

• Drugs to obesity control and/or oral corticosteroids anti-inflammatory in the last three months